Document Classification

Section Type: RESULTS

Text: The eyes of patients in the pooled alemtuzumab group (versus IFNB-1a) had a greater than 2-fold higher rate of both 3-month and 6-month sustained visual improvement, of at least 0. 3 log units (2 triplets, 6 letters) (At 3 months the hazard ratio (HR) = 2. 26 ; CI = 1. 19 to 4. 31 ; P = 0. 013 ; and at 6 months the HR = 2. 44 ; CI = 1. 16 to 5. 15 ; P = 0. 019), and they had a lower risk of 3 - and 6-month sustained worsening of at least 0. 15 log units (1 triplet, 3 letters) (At 3 months the HR = 0. 58 ; CI = 0. 38 to 0. 89 ; P = 0. 012 ; and at 6 months HR = 0. 55 ; CI = 0. 35 to 0. 87 ; P = 0. 010).